2Osch GJ, Kraan PM, Valburg AA, et al. The relation between cartilage damage and osteophyte size in a murine model for osteoarthritis in the knee. Rheumatol Int, 1996,16(3) : 115-119.
3Muir H. Articular cartilage biochemistry. Raven Press New, 1986.
4Martel PJ,McCollum R,Fujimoto N,et al. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest,1994,70:807-815.
5Bian J ,Sun Y. Transcriptional activation by p53 of the human type Ⅳ collagenase (gelatinase A or matrix metalloproteinase 2)promoter. Mol Cell Biol, 1997,17 : 6330-6338.
6Yoshihara Y,Obata K, Fujimoto N, et al. Serum mad synovial fluid levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases in patients with osteoarthritis. Arthritis Rheum, 1995, 38(7) : 969-975.
7Ohta S, Imai K, Yamashita K,et al. Expression of matrix metalloproteinase 7 (matrilysin) in human osteoarthritic cartilage. Lab Invest,1998,78: 79-87.
8Flannery CR,Little CB, Caterson B, et al. Effects of culture conditions and exposure to catabolic stimulators (IL-1 and retinoic acid) on the expression of matrix metalloproteinases (MMPs) and disintegrin metalloproteinases (ADAMs) by articular cartilage chondrocytes. Matrix Biol, 1999,18(3) :225-237.
9Wu CW, Tchetina EV, Mwale F, et al. Proteolysis involving matrix metalloproteinase 13 (collagenase-3) is required for chondrocyte differentiation that is associated with matrix mineralization. J Bone Miner Res,2002,17(4) :639-651.
10Kubota T, Kubota E, Matsumoto A, et al. Identification of matrix metalloproteinases (MMPs) in synovial fluid from patients with temporomandibular disorder. Eur J Oral Sci, 1998,106(6) :992-998.
